Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Program Bridges Gap to Develop New Therapeutics

Published: Wednesday, December 18, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
New projects advance treatments for acute radiation syndrome, brain injury from cardiac arrest and a rare blood disorder.

The National Institutes of Health has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia.

The projects are part of the Bridging Interventional Development Gaps (BrIDGs) program, which is funded by the NIH Common Fund and led by NIH's National Center for Advancing Translational Sciences (NCATS).

BrIDGs provides eligible scientists with no-cost access to contractor services, such as toxicology studies, for pre-clinical therapeutic development. To be eligible for the program, projects must have been effective in a disease model.

Researchers often apply to BrIDGs because they have hit a roadblock and need additional expertise or lack other resources. Rather than funding successful applicants directly, BrIDGs supports expert NIH contractors who perform pre-clinical services for the researchers free-of-charge.

"BrIDGs researchers and partner scientists work together to bridge the gap between a basic discovery and clinical testing, thereby ensuring potential treatments have a chance to reach patients who need them," said Christopher P. Austin, M.D., NCATS director.

A primary goal of a BrIDGs project is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin human clinical trials. To date, BrIDGs scientists have generated data to support 12 INDs submitted to the FDA, as well as one clinical trial application to Health Canada. They also have evaluated 12 of the 13 projects in clinical trials.

Three BrIDGs-supported therapeutic agents have gone as far as Phase II clinical trials, in which researchers provide an experimental therapy to a group of patients to evaluate its safety and effectiveness. Third-party investors have licensed seven compounds during or after their development through the BrIDGs program.

BrIDGs scientists selected the following new projects from the 2013 application solicitation:

Acute Radiation Syndrome
Manufacturing of RLIP76-LyoPL for Acute Radiation Syndrome Henry Hebel, M.B.A., vice president of drug development Terapio Corp., Austin, Texas

Exposure to radiation, whether from a compromised nuclear reactor or a radiation weapon, can lead to acute radiation syndrome, a life-threatening multi-organ illness. Currently, there is no FDA-approved treatment for the syndrome. This project is designed to develop a treatment that can be administered beginning 24 hours or longer after radiation exposure. NIH's National Institute of Allergy and Infectious Diseases is co-funding the pre-clinical studies for this project through its Radiation Nuclear Countermeasures Program.

Beta Thalassemia
The Development of Minihepcidins for the Treatment of Beta Thalassemia Brian MacDonald, Ph.D., president and CEO Merganser Biotech LLC, Newtown Square, Pa.

Patients with beta thalassemia, a rare inherited blood disorder, suffer from severe anemia and iron overload that can damage the heart. The disorder reduces production of hepcidin, the iron regulatory hormone. The goal of this project is to develop a treatment that increases levels of hepcidin and lowers the damaging effects of too much iron. NIH's National Institute of Diabetes and Digestive and Kidney Diseases is co-funding this project.

Cardiac Arrest-Induced Acute Brain Injury
HBN-1 Regulated Hypothermia Formulation and Evaluation of Toxicity Laurence Katz, M.D., associate professor of emergency medicine University of North Carolina at Chapel Hill

Patients resuscitated from cardiac arrest can suffer from acute brain injury. Lowering a patient's body temperature into therapeutic-induced hypothermia can improve survival with good neurological outcomes in more than half of patients who remain in a coma after cardiac arrest. This project is designed to develop HBN-1 as an intravenous treatment that paramedics can give to cardiac arrest patients to induce hypothermia sooner. The NIH Common Fund is funding the pre-clinical studies for this project.

"Although each project is selected for its scientific merit, not all projects will lead to treatments because the pre-clinical phase of drug development is fraught with failures related to issues such as adverse side effects," said John McKew, Ph.D., acting director of NCATS' Division of Pre-clinical Innovation and chief of the Therapeutics Development Branch. "Still, the support that BrIDGs provides gives each project a fighting chance."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Monday, July 25, 2016
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Saturday, July 23, 2016
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Thursday, July 21, 2016
Brain Circuits Helps People Cope With Stress
Researchers at NIH have identified brain patterns in humans that appear to underlie “resilient coping,” to stress that help some people handle stressful situations better than others.
Wednesday, July 20, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Wednesday, July 13, 2016
Use it or Lose it: Visual Activity Regenerates Links Between Eye, Brain
The mouse study is first to show visual stimulation helps re-wire visual system and partially restores sight.
Tuesday, July 12, 2016
NIH Funds Million-Person Medicine Study
NIH announces $55million in awards to build foundations for ambitious Cohort Program that aims to engage 1 million participants in lifestyle, environments and genetics research.
Friday, July 08, 2016
Largest-Ever Study of Breast Cancer Genetics in Black Women
The study will identify genetic factors that may underlie breast cancer disparities.
Thursday, July 07, 2016
NIH-Funded Center to Study Inefficiencies in Clinical Trials
Researchers at the Duke Clinical Research Institute (DCRI) and Vanderbilt University Medical Center (VUMC) have received a major federal grant to study how multisite clinical trials of new drugs and therapies in children and adults can be conducted more rapidly and efficiently.
Thursday, July 07, 2016
NIH Funds Zika Virus Study Involving U.S. Olympic Team
Researchers will monitor potential Zika virus exposure among a subset of athletes traveling to Brazil.
Wednesday, July 06, 2016
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
Wednesday, July 06, 2016
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Friday, July 01, 2016
Significant Expansion Of Data Available In The Genomic Data Commons
Cancer genomic profile information from 18,000 adult cancer patients will be added to the database.
Wednesday, June 29, 2016
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Tuesday, June 28, 2016
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be pair with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Core-Shell Columns in HPLC: Food Analysis Applications
Explore the most recent applications of core-shell columns in food analysis.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!